New options for migraine treatment: Focus on CGRP-blocking antibodies

M. Dux, K. B. Messlinger

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Pharmacotherapy of migraine pain has largely been focused on calcitonin gene-related peptide (CGRP), a vasoactive neuropeptide mainly released from activated primary afferents. CGRP has multiple effects in different central and peripheral systems but its migraine promoting actions are widely unclear. Current clinical and experimental principles are based on reducing stimulated CGRP release by 5-HT1B/D agonists (triptans) and inhibiting its receptors by nonpeptide CGRP receptor antagonists ("gepants"). Triptans are ineffective in a variety of patients and their frequent use may cause medication overuse headache, while further development of gepants has been interrupted due to side effects. Development and clinical trials of humanized monoclonal antibodies targeting CGRP or its receptors appear promising as a new strategy in the therapy of the growing problem of chronic migraine. This review discusses critically the sites and effects of CGRP receptor activation and inhibition in and outside of the trigeminal system relevant for the efficacy and safety of preventive therapeutic strategies targeting CGRP signaling.

Original languageEnglish
Pages (from-to)589-599
Number of pages11
JournalDrugs of the Future
Volume40
Issue number9
DOIs
Publication statusPublished - Sep 1 2015

Fingerprint

Blocking Antibodies
Calcitonin Gene-Related Peptide
Migraine Disorders
Calcitonin Gene-Related Peptide Receptors
Tryptamines
Secondary Headache Disorders
Serotonin 5-HT1 Receptor Agonists
Therapeutics
Antibodies, Monoclonal, Humanized
Neuropeptides
Clinical Trials
Safety
Drug Therapy
Pain

Keywords

  • Anti-CGRP - Migraine - TEV-48125 - LY-2951742 - ALD-403 - AMG-334 - Antibodies

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

New options for migraine treatment : Focus on CGRP-blocking antibodies. / Dux, M.; Messlinger, K. B.

In: Drugs of the Future, Vol. 40, No. 9, 01.09.2015, p. 589-599.

Research output: Contribution to journalArticle

Dux, M. ; Messlinger, K. B. / New options for migraine treatment : Focus on CGRP-blocking antibodies. In: Drugs of the Future. 2015 ; Vol. 40, No. 9. pp. 589-599.
@article{e4fed7fdd9b74fbcb0e9df0172e26346,
title = "New options for migraine treatment: Focus on CGRP-blocking antibodies",
abstract = "Pharmacotherapy of migraine pain has largely been focused on calcitonin gene-related peptide (CGRP), a vasoactive neuropeptide mainly released from activated primary afferents. CGRP has multiple effects in different central and peripheral systems but its migraine promoting actions are widely unclear. Current clinical and experimental principles are based on reducing stimulated CGRP release by 5-HT1B/D agonists (triptans) and inhibiting its receptors by nonpeptide CGRP receptor antagonists ({"}gepants{"}). Triptans are ineffective in a variety of patients and their frequent use may cause medication overuse headache, while further development of gepants has been interrupted due to side effects. Development and clinical trials of humanized monoclonal antibodies targeting CGRP or its receptors appear promising as a new strategy in the therapy of the growing problem of chronic migraine. This review discusses critically the sites and effects of CGRP receptor activation and inhibition in and outside of the trigeminal system relevant for the efficacy and safety of preventive therapeutic strategies targeting CGRP signaling.",
keywords = "Anti-CGRP - Migraine - TEV-48125 - LY-2951742 - ALD-403 - AMG-334 - Antibodies",
author = "M. Dux and Messlinger, {K. B.}",
year = "2015",
month = "9",
day = "1",
doi = "10.1358/dof.2015.040.09.2383047",
language = "English",
volume = "40",
pages = "589--599",
journal = "Drugs of the Future",
issn = "0377-8282",
publisher = "Prous Science",
number = "9",

}

TY - JOUR

T1 - New options for migraine treatment

T2 - Focus on CGRP-blocking antibodies

AU - Dux, M.

AU - Messlinger, K. B.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Pharmacotherapy of migraine pain has largely been focused on calcitonin gene-related peptide (CGRP), a vasoactive neuropeptide mainly released from activated primary afferents. CGRP has multiple effects in different central and peripheral systems but its migraine promoting actions are widely unclear. Current clinical and experimental principles are based on reducing stimulated CGRP release by 5-HT1B/D agonists (triptans) and inhibiting its receptors by nonpeptide CGRP receptor antagonists ("gepants"). Triptans are ineffective in a variety of patients and their frequent use may cause medication overuse headache, while further development of gepants has been interrupted due to side effects. Development and clinical trials of humanized monoclonal antibodies targeting CGRP or its receptors appear promising as a new strategy in the therapy of the growing problem of chronic migraine. This review discusses critically the sites and effects of CGRP receptor activation and inhibition in and outside of the trigeminal system relevant for the efficacy and safety of preventive therapeutic strategies targeting CGRP signaling.

AB - Pharmacotherapy of migraine pain has largely been focused on calcitonin gene-related peptide (CGRP), a vasoactive neuropeptide mainly released from activated primary afferents. CGRP has multiple effects in different central and peripheral systems but its migraine promoting actions are widely unclear. Current clinical and experimental principles are based on reducing stimulated CGRP release by 5-HT1B/D agonists (triptans) and inhibiting its receptors by nonpeptide CGRP receptor antagonists ("gepants"). Triptans are ineffective in a variety of patients and their frequent use may cause medication overuse headache, while further development of gepants has been interrupted due to side effects. Development and clinical trials of humanized monoclonal antibodies targeting CGRP or its receptors appear promising as a new strategy in the therapy of the growing problem of chronic migraine. This review discusses critically the sites and effects of CGRP receptor activation and inhibition in and outside of the trigeminal system relevant for the efficacy and safety of preventive therapeutic strategies targeting CGRP signaling.

KW - Anti-CGRP - Migraine - TEV-48125 - LY-2951742 - ALD-403 - AMG-334 - Antibodies

UR - http://www.scopus.com/inward/record.url?scp=84946842059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946842059&partnerID=8YFLogxK

U2 - 10.1358/dof.2015.040.09.2383047

DO - 10.1358/dof.2015.040.09.2383047

M3 - Article

AN - SCOPUS:84946842059

VL - 40

SP - 589

EP - 599

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 9

ER -